Results of the FAST trial presented at #ACR20 - Safety study required by the EMA - Febuxostat non-inferior to allopurinol for any outcomes - Long-term use of febuxostat is not associated with an increased risk of death Published in @TheLancet today https://t.co/EvJGPpDCR8

• DEFINE_ME

Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovascular events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat @rheumnow #ACR20 Abstr#L08 #ACRbest

A new (better) approach to #rheumatic disease treatment has to include wellness, lifestyle, and beyond. And this includes #empathy, says @LCalabreseDO at #ACR20. https://t.co/paE1Io6uvC

With Phase 2 of the Accelerating Medicines Partnership study of SLE underway, an #ACR20 session featured a panel that reviewed the methods being used to generate data & discussed some of the findings. Read the recap → https://t.co/hTnCdfBn10

• Panel discusses emerging molecular insights from AMP SLE Network - ACR Converge…

Just watched David Beck’s talk on somatic mutations in VEXAS. Genotyping to link phenotypically diverse disease. Such an exciting strategy to identify additional unknown diseases!!! #ACR https://t.co/gU9HEZyjRP

FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/FkdDtPB4Oi https://t.co/J9KonQHpT2

• https://meet.acrconvergence.org/meetings/bFG6BTawj43DP9SbX

Listen to part II of our #ACR20 Day 3 recap. Follow the link below or find us on Apple podcasts. https://t.co/1TcXfU5TMg https://t.co/evGkn9UARB

• https://bit.ly/2U7iReS

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

Does IL-6 blockade prevent mechanical ventilation or death in #COVID19? MGH study by Dr. Stone Abst#L07 graph shows no benefit @RheumNow #ACR20 https://t.co/DHfHYJCkod

Patient-physician discordance seen in ~30% #rheumatoidarthritis patients starting #DMARDs - ↑Patient-reported pain & functional impairment assoc. w/ discordance - Patient-centric treatment discussions needed to reduce discordance Abs#1978 #ACR20 @RheumNow https://t.co/CdlHrBOdy0

• Prevalence and Factors Associated with Patient-Physician Discordance Among RA P…

The avacopan story, stronger again: (recall: avacopan targets C5aR) endogenous anti-C5aR1 in GPA inversely correlates with dx activity, relapse questions, via chair @philseo: What happens to anti-C5aR1 with Rx? Does this influence therapeutic strategy? #ACR20 ABST2050 @RheumNow https://t.co/g4JfjQal8R

Very strong push by #ACR20 to recc MTX in most RA patient scenarios including RA ILD, RA nodules, NAFLD in new RA guidance document @rheumnow

Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038. @rheumnow @DrPujaMehta1 #ACR20 Abstr#L06 #ACRbest https://t.co/MTuH0sAuWt

You have a patient with RA on 25 mg MTX SQ, tolerating well without side effects. They have moderate disease activity. Your next step: @Rheumnow. #ACR20